LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

LLY

734.37

-0.09%↓

JNJ

176.67

-0.01%↓

ABBV

208.05

-0.2%↓

UNH

303.9

+1.02%↑

AZN

79.94

-0.17%↓

Search

Adaptive Biotechnologies Corp

Cerrado

12.95 1.25

Resumen

Variación precio

24h

Actual

Mínimo

12.58

Máximo

12.98

Métricas clave

By Trading Economics

Ingresos

4.2M

-26M

Ventas

6.4M

59M

Margen de beneficio

-43.467

Empleados

619

EBITDA

11M

-18M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+7.42% upside

Dividendos

By Dow Jones

Próximas Ganancias

6 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

272M

1.9B

Apertura anterior

11.7

Cierre anterior

12.95

Puntuación técnica

By Trading Central

Confianza

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

27 ago 2025, 22:51 UTC

Ganancias

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

27 ago 2025, 23:57 UTC

Ganancias

Trip.com Group 1H Rev $4.01B

27 ago 2025, 23:57 UTC

Ganancias

Trip.com Group 1H Adj EPS $1.84

27 ago 2025, 23:57 UTC

Ganancias

Trip.com Group 1H EPS $1.82

27 ago 2025, 23:50 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

27 ago 2025, 23:39 UTC

Ganancias

Correction to Nvidia Earnings Article -- WSJ

27 ago 2025, 22:59 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 ago 2025, 22:59 UTC

Charlas de Mercado

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

27 ago 2025, 22:58 UTC

Ganancias

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

27 ago 2025, 22:57 UTC

Ganancias

South32 FY Free Cash Flow $192 Million

27 ago 2025, 22:56 UTC

Ganancias

South32 FY Total Capital Expenditure $1.35 Billion

27 ago 2025, 22:56 UTC

Ganancias

South32 FY Capital Expenditure $963 Million, Excluding EAIs

27 ago 2025, 22:55 UTC

Ganancias

South32 Net Cash $123 Million at June 30

27 ago 2025, 22:54 UTC

Ganancias

South32: Focused on Maintaining Strong Operating Momentum

27 ago 2025, 22:53 UTC

Ganancias

South32: $144 Million Remains to be Returned to Shareholders Under Program

27 ago 2025, 22:53 UTC

Ganancias

South32 Extends Capital Management Program for 12 Months

27 ago 2025, 22:52 UTC

Ganancias

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

27 ago 2025, 22:51 UTC

Ganancias

South32 FY Revenue $5.78 Billion, Up 17% On-Year

27 ago 2025, 22:51 UTC

Ganancias

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

27 ago 2025, 22:50 UTC

Ganancias

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

27 ago 2025, 22:50 UTC

Ganancias

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

27 ago 2025, 22:45 UTC

Ganancias

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

27 ago 2025, 22:44 UTC

Ganancias

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

27 ago 2025, 22:44 UTC

Ganancias

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

27 ago 2025, 22:43 UTC

Ganancias

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

27 ago 2025, 22:43 UTC

Ganancias

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

27 ago 2025, 22:42 UTC

Ganancias

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

27 ago 2025, 22:42 UTC

Ganancias

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

27 ago 2025, 22:40 UTC

Ganancias

Sandfire Resources Net Debt $123 Million at June 30

27 ago 2025, 22:40 UTC

Ganancias

Sandfire Resources FY Underlying Ebitda $527.7 Million

Comparación entre iguales

Cambio de precio

Adaptive Biotechnologies Corp Esperado

Precio Objetivo

By TipRanks

7.42% repunte

Estimación a 12 meses

Media 13.75 USD  7.42%

Máximo 15 USD

Mínimo 11 USD

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Adaptive Biotechnologies Corp Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

7 ratings

6

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.81 / 10.18Soporte y Resistencia

Corto Plazo

Very Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Weak Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.